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Summary 
X-linked recessive chondrodysplasia punctata (CDPX) 
is a congenital defect of bone and cartilage develop- 
ment characterized by aberrant bone mineralization, 
severe underdevelopment of nasal cartilage, and dis- 
tal phalangeal hypoplasia. A virtually identical pheno- 
type is observed in the warfarin embryopathy, which is 
due to the teratogenic effects of coumarin derivatives 
during pregnancy. We have cloned the genomic region 
within Xp22.3 where the CDPX gene has been assigned 
and isolated three adjacent genes showing highly sig- 
nificant homology to the sulfatase gene family. Point 
mutations in one of these genes were identified in five 
patients with CDPX. Expression of this gene in COS 
cells resulted in a heat-labile arylsulfatase activity that 
is inhibited by warfarin. A deficiency of a heat-labile 
2Present address: Telethon Institute of Genetics and Medicine (TIGEM), 
San Raffaele Biomedical Science Park, Via Olgettina 58, 20132 Mi- 
lano, Italy. 
arylsulfatase activity was demonstrated in patients 
with deletions spanning the CDPX region. These data 
indicate that CDPX is caused by an inherited deficiency 
of a novel sulfatase and suggest that warfarin era- 
bryopathy might involve drug-induced inhibition of the 
same enzyme. 
Introduction 
The sulfatases are a group of enzymes that hydrolyze sul- 
fate ester bonds in a wide variety of structurally different 
compounds, ranging from complex molecules, such as 
glycosaminoglycans and sulfolipids, to 31B-hydroxysteroid 
sulfates (Ballabio and Shapiro, 1995). Nine different hu- 
man sulfatases have been described and characterized 
biochemically (for reviews see Ballabio and Shapiro, 1995; 
Kolodny and Fluharty, 1995; Neufeld and Muenzer, 1995). 
The importance of these proteins in human metabolism 
is emphasized by the presence of seven distinct inherited 
disorders resulting from specific sulfatase deficiencies 
(Kolodny and Fluharty, 1995; Neufeld and Muenzer, 1995). 
The evidence that sulfatases are members of a family 
of related proteins, probably sharing acom mon ancestor, 
is both structural and functional. The cloning and sequenc- 
ing of six human sulfatase cDNAs (Ballabio et al., 1987; 
Yen et al., 1987; Robertson et al., 1988; Stein et al., 1989a; 
Peters et al., 1990; Schuchman et al., 1990; Wilson et al., 
1990; Tomatsu et al., 1991), of a sea urchin arylsulfatase 
cDNA (Sasaki et al., 1988), and of Escherichia coil (Daniels 
et al., 1992) and Klebsiella aerogenes (Murooka et al., 
1990) arylsulfatases have revealed a high degree of ho- 
mology along the entire length of these proteins, particu- 
larly in the N-terminal regions, suggesting that specific 
motifs in the amino acid sequence are important for sul- 
fatase activity (Wilson et al., 1990). Additional evidence 
that all sulfatases are functionally related comes from the 
study of a rare and intriguing enetic disease named multi- 
ple sulfatase deficiency (MSD), in which all known sul- 
fatases are deficient (Kolodny and Fluharty, 1995). This 
autosomal recessive disorder may be due to an abnormal- 
ity in a posttranslational event common to all sulfatases. 
Three of the previously described human sulfatases, 
known as arylsulfatases A, B, and C (ARSA, ARSB, and 
ARSC), are able to hydrolyze sulfated artificial substrates 
containing a phenolic ring, such as p-nitrocatechol sulfate 
or 4-methylumbelliferyl sulfate (4-MU sulfate) (Kolodny 
and Fluharty, 1995). ARSC is more specifically known as 
steroid sulfatase (STS) because of its ability to hydrolyze 
steroid sulfates. While ARSA, ARSB, and ARSC each act 
on a distinct natural substrate, they all have a "promiscu- 
ous" activity against artificial substrates (arylsulfatase ac- 
tivity). ARSA and ARSB are lysosomal in their subcellular 
localization and have acidic pH optima, while ARSC is 
microsomal and has a neutral to alkaline pH optimum (Bal- 
labio and Shapiro, 1995). 
The term "chondrodysplasia punctata" refers to a group 
of skeletal dysplasias characterized by abnormal calcium 
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deposition in regions of enchondral bone formation. This 
abnormality results in a peculiar adiological finding, com- 
monly referred to as "stippling" of epiphyses or "paint- 
spattered" calcifications. These calcifications tend to disap- 
pear within the first few years of life as bone development 
progresses. Chondrodysplasia punctata is heterogeneous 
both at the genetic and clinical evels, and only a few dis- 
tinct entities with different patterns of inheritance and vari- 
able degrees of severity appear to be fairly well characterized 
(Spranger et al., 1970). A specific type of chondrodyspla- 
sia punctata is associated with nullisomy of the distal short 
arm of the human X chromosome (Xp22.3) in males with 
deletions and translocations involving this region (Curry 
et al., 1984). These patients have contiguous gene syn- 
dromes due to the involvement of adjacent disease genes 
on Xp22.3 (Ballabio and Andria, 1992). Affected individu- 
als display facial dysmorphism characterized by severe 
nasal hypoplasia, depressed nasal bridge, short nasal 
septum, and a deep groove between the nasal alae and 
the tip. They also have short stature and distal phalangeal 
hypoplasia, the latter being particularly evident by radio- 
logical examination. Punctate stippling of multiple piphy- 
seal centers is observed in the neonatal and early infancy 
periods and usually disappears with age. There is strong 
genetic evidence that this mild and rather distinct ype of 
chondrodysplasia punctata, referred to as X-linked reces- 
sive chondrodysplasia punctata (CDPX; MIM302950), is 
due to the loss of function of a specific gene on Xp22.3 
(for review see Ballabio and Andria, 1992). 
A phenotype clinically indistinguishable from that of 
CDPX has also been described in a few patients with no 
visible or molecularly detectable chromosomal abnormal- 
ity (Sheffield et al., 1976; Maroteaux, 1989). Although 
some of these patients may carry point mutations in the 
putative CDPX gene, as most of them lack a positive family 
history, the possibility of genetic heterogeneity for the 
CDPX phenotype should be considered. 
Interestingly, CDPX shows remarkable phenotypic simi- 
larities to two well-characterized isease entities involving 
vitamin K metabolism and function: warfarin embryopathy 
and vitamin K epoxide reductase deficiency. Warfarin em- 
bryopathy is caused by the administration of warfarin, an 
anticoagulant drug, during a critical period of 6-9 weeks 
of pregnancy (for review see Hall et al., 1980). Vitamin K 
epoxide reductase deficiency, also known as pseudowar- 
farin embryopathy, is a rare autosomal recessive disorder 
affecting the recycling of vitamin K (Pauli et al., 1987; 
Pauli, 1988). Both of these disorders display abnormalities 
of cartilage and bone development hat are strikingly simi- 
lar to those observed in CDPX. The phenotypic similarities 
among CDPX, warfarin embryopathy, and vitamin K epox- 
ide reductase deficiency suggest the possibility that ge- 
netic and drug-induced defects underlying thase syn- 
dromes may affect the same metabolic pathway. 
Over 50 patients carrying deletions and translocations 
involving the Xp22.3 region and displaying features of 
CDPX have been described (for review see Ballabio and 
Andria, 1992). Molecular genetic analysis of some of these 
patients has defined the critical genomic region that must 
contain the CDPX gene (Wang et al., 1995). In this study, 
we report the isolation from this region of a cluster of genes 
showing a significant homology to all members of the sul- 
fatase gene family. Point mutations in one of these genes, 
named arylsulfatase E (ARSE), were identified in five pa- 
tients with CDPX, indicating that this disorder is caused 
by a sulfatase deficiency. Transfection of ARSE cDNA 
into COS cells results in an arylsulfatase activity that is 
inhibited bywarfarin, providing insight into the pathogene- 
sis of warfarin embryopathy. 
Results 
Identification of Three Novel Sulfatase Genes 
on Xp22.3 
In a recent study, we described the assignment of the 
CDPX gene to a specific genomic segment of 600 kb lo- 
cated approximately 150 kb centromeric to the pseudoau- 
tosomal boundary on Xp22.3 (Wang et al., 1995). Overlap- 
ping yeast artificial chromosome (YAC) clones spanning 
this entire region were isolated and partially characterized. 
Two YAC clones, NB6F12 and 455B10, were purified by 
pulsed-field gel electrophoresis (PFGE) and hybridized to 
an arrayed X chromosome-specific osmid library ob- 
tained from Lawrence Livermore laboratories, as pre- 
viously described (Wapenaar et al., 1994). Two groups of 
overlapping cosmid clones were identified and used in 
exon trapping experiments in order to identify candidate 
genes for CDPX (Figure 1). DNA from cosmids 18, 76, 75, 
48, 32, 66, 58, 96, and 100 was subcloned into the pSPL3 
vector (Church et al., 1994), and exon amplification prod- 
ucts were blotted and hybridized to the corresponding cos- 
mid DNA. Several putative xons were identified using this 
strategy and were characterized by reverse transcription- 
polymerase chain reaction (RT-PCR) using RNAs from 
several tissues (data not shown), by sequence analysis, 
and by hybridization to the DNA from patients BA169 and 
BA311. Five different exons were found to map back to 
the CDPX critical region and to be expressed based on 
RT-PCR. Their position with respect to YAC and cosmid 
clones from the region is shown in Figure 1. 
Sequence analysis of these five exons was determined, 
and nonredundant DNA and protein data bases were 
searched using the BLAST-X, BLAST-P, and TBLAST-N 
algorithms. Striking similarities were identified with all pre- 
viously described members of the sulfatase gene family, 
including sulfatases from distantly related species such 
as bacteria. The highest homology scores for each of the 
five exons were with the STS (ARSC) sequence. 
The relative position of the five exons in the cosmid 
map and the alignment with previously described sulfatase 
sequences (STS in particular) led us to conclude that these 
exons must be derived from at least two distinct genes. 
This was confirmed by subsequent cDNA identification 
and characterization. PCR products from exons 76.15, 
18.12, and 48.7 were hybridized to a human kidney cDNA 
library. Several overlapping cDNA clones from two distinct 
transcription units were isolated: exons 76.15 and 18.12 
identified 6 cDNA clones, while exon 48.7 identified 21 
clones. 
A consensus full-length sequence was determined for 
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Figure 1. Physical Mapping of the CDPX Criti- 
cal Region 
The CDPX critical region is defined by the 
breakpoints of patients BA311 and BA169 
(Wang et al., 1995). YAC clones are shown as 
thick bars. Closed circles show the position of 
single-copy probes used for YAC identification 
and for the assembly of the YAC contig. Thin 
bars indicate cosmid clones used for the exon 
amplification experiments. Putative xons are 
depicted as closed boxes. The position and ori- 
entation of transcription ofthe three novel sut- 
fatase genes isolated from the region are 
shown at the bottom. The orientation oftran- 
scription of the ARSF gene is unknown. PABX, 
pseudoautosomal boundary on the X chromo- 
some. 
both transcripts. Owing to their high degree of homology 
with arylsulfatases and based on the results of functional 
analyses (see below), these two genes were named ARSD 
and ARSE. The orientation of transcription of the genes 
is centromere to telomere, as shown in Figure 1. Both 
genes appear to have a single copy located in the Xp22.3 
region. However, some cDNA fragments detect Y chromo- 
some-specific bands by Southern blot analysis (data not 
shown). A detailed characterization of the genomic struc- 
ture of the two genes will be reported elsewhere. 
Hybridization of cDNA probes to cosmid clones 18, 76, 
75, and 48 (see Figure 1) from the CDPX critical region 
revealed that the two genes did not cross-hybridize to each 
other, with the exception of a small region in the vicinity 
of their 3' ends. Probes spanning this region of the cDNA 
also hybridized to cosmids 58 and 96, suggesting the pres- 
ence of a third homologous gene. To investigate this hy- 
pothesis, cosmid 96 was digested with Sau3A and sub- 
cloned into a plasmid vector. Plasmid clones hybridizing 
to the cDNA clones were sequenced, and a region of high 
homology to sulfatase cDNAs was identified. This region 
of homology was flanked by consensus splice sequences, 
indicating that it corresponded to an exon. Preliminary 
data obtained by both RT-PCR and Northern blot analysis 
indicate that this exon belongs to a transcribed gene, 
which we named ARSF because of the extremely high 
degree of homology with ARSD and ARSE (Figure 2). 
Analysis of ARSD and ARSE cDNA Sequences 
ARSD consensus cDNA sequence (1945 bp) was assem- 
bled by analysis of sequences from four cDNA clones and 
partly from the corresponding enomic clones. The au- 
thenticity of the 5' end was validated by 5'-RACE-PCR 
experiments and by sequencing the corresponding eno- 
mic region. The putative initiation codon was identified 
at position 77 and the first in-frame stop codon (TGA) at 
nucleotide 1856, resulting in a predicted protein of 594 
amino acids. ARSE consensus cDNA sequence (1858 bp) 
was assembled from the analysis of 13 cDNA clones and 
of several exon-containing genomic clones. The authentic- 
ity of the 5' end was validated by comparing the sequence 
of several overlapping cDNA clones and by sequencing 
the corresponding enomic region. The putative initiation 
codon was identified at nucleotide 68, a polyadenylation 
site AATAA at position 1833, and the first in-frame stop 
codon at 1835, resulting in a predicted protein of 590 
amino acids. Interestingly, this stop codon (TAA) is part 
of the polyadenylation site, resulting in an extremely short 
3' untranslated region. 
Figure 2 shows the results of the alignment of the ARSD, 
ARSE, and ARSF predicted protein products with previously 
reported glucosamine-6-sulfatase (G6S), iduronate sul- 
fatase (IDS), N-acetylgalactosamine-6-sulfatase (Gal6S), 
ARSA, ARSB, and ARSC/STS proteins. The homology is 
particularly high near the N-terminus, where a putative 
active site of some of these enzymes is thought to reside 
(Wilson et al., 1990). A region with low amino acid identity, 
corresponding to a transmembrane domain in ARSC/STS 
(Stein et al., 1989b), is found in G6S, IDS, ARSC/STS, 
ARSD, and ARSE and is absent in Gal6S, ARSA, and 
ARSB. The highest identity scores were found when com- 
paring ARSD with ARSE and when comparing these two 
with ARSC/STS, indicating that these three genes are 
much more closely related to each other than to the other 
members of the family. 
ARSD and ARSE Expression Pattern 
Northern blot analysis of ARSD and ARSE mRNAs re- 
vealed different expression patterns for these two genes. 
ARSD cDNA probes detected both a 5 kb transcript and a 
much less abundant 3.5 kb transcript in pancreas, kidney, 
liver, lung, placenta, brain, and heart (Figure 3A). Pan- 
creas and kidney showed relatively higher levels of expres- 
sion. Under the same conditions, probes from the ARSE 
gene detect a very abundant 2.2 kb and a less abundant 
4 kb transcript (Figure 3B). ARSE mRNA is much more 
abundant compared with ARSD (Figures 3A and 3B have 
different exposure times) and appears to have a more dis- 
crete tissue distribution, being expressed exclusively in 
pancreas, liver, and kidney among all the tissues tested. 
Preliminary data indicate that the different forms of ARSD 
and ARSE transcripts are generated by the use of different 
polyadenylation sites, resulting in different lengths of the 
3' untranslated region. 
Detection of ARSD and ARSE mRNAs in cultured cell 
lines by RT-PCR allowed us to test the X-inactivation sta- 
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Figure2. Homology among ARSD, ARSE, 
and ARSF Predicted Protein Products and Pre- 
viously Reported Human Sulfatases 
G6S, glucosamine-6-sulfatase, IDS, iduronate 
sulfatase, Gal6S, N-acetylgalactosamine-6-sul- 
fatase, ARSA, arylsulfatase A, ARSB, arylsul- 
fatase B, ARSC, arylsulfatase C/STS. Amino 
,acids that are identical at least in ARSC, ARSD, 
ARSE, an d ARSF are writte n in white on a black 
background. Only partial sequence informa- 
tion is available for ARSF. The position of the 
five mutations in the ARSE gene found in pa- 
tients with CDPX is indicated by a star below 
the sequence. 
tus of these two genes. Reverse-transcribed RNA samples 
from a male control and a hybrid cell line retaining the 
inactive X chromosome were amplified by PCR using oli- 
gonucleotide primers generated from the cDNA se- 
quences. As shown in Figure 3C, both ARSD and ARSE 
mRNAs were detected in the male control and in the hybrid 
cell line, indicating that these genes are expressed by both 
the active and the inactive X chromosomes, thus escaping 
X-inactivation. 
Searching for Mutations in Patients with CDPX 
Twenty-seven unrelated male patients with radiological 
and/or clinical features of CDPX, but with no reported chro- 
mosomal abnormality involving the Xp22.3 region, were 
tested for small rearrangements or point mutations in the 
ARSD and the ARSE genes. Full-length cDNAs from these 
genes were used as probes for Southern blot analysis 
on EcoRl-, Hindlll-, and Taql-digested genomic DNA from 
patients. A normal restriction pattern was detected in all 
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Figure 3. Northern Blot and RT-PCR Analyses of the ARSD and 
ARSE Genes 
(A) Poly(A) + RNA from multiple tissues hybridized to probe 76.15, one 
of the exon amplification products from the ARSD gene. A -5  kb 
transcript abundant in kidney and pancreas but present also in liver, 
lung, placenta, brain, and heart is detected. A much less abundant 
transcript of -3.5 kb is also visible in the same tissues. 
(B) A different Northern blot containing RNA samples from the same 
tissues was hybridized to probe 48.7, an exon amplification product 
from the ARSE gene. A very abundant 2.2 kb transcript and a less 
abundant 4 kb transcript are detected in pancreas, kidney, and liver. 
(C) X inactivation studies ofARSD and ARSE genes. Oligonucleotide 
primers from ARSD and ARSE cDNAs were used for the amplification 
of reverse-transcribed total RNA from a normal male fibroblast cell 
line (XY), from a human/hamster hybrid cell line retaining the human 
inactive X chromosome (Xi), and from a hamster cell line. Plus and 
minus indicate presence and absence of reverse transcriptase in the 
RT reaction. ARSD and ARSE primers amplify a 148 bp and a 450 bp 
product, respectively, from both the active and inactive X chromosome 
(left panels). As controls, oligonucleotide primers from MIC2 gene, 
known to escape X inactivation, and PGK1 gene that is expressed 
only by the active X chromosome were used to amplify the same tem- 
plates (right panels). 
patients. To test for the presence of point mutations, the 
sequence of most intron-exon boundaries of both ARSD 
and ARSE genes was determined, and ol igonucleotide 
primers were generated to amplify single exons. Amplif ied 
exons were tested by single strand conformation polymor- 
phism (SSCP), and several band mobility shifts were iden- 
tified. Each of the exons in which a band mobil ity shift was 
identified was tested by SSCP on 60 female controls (a 
total of 120 normal X chromosomes) to exclude a polymor- 
phisrn. A total of 4 out of 10 exons were tested for ARSD 
and 9 out of 11 exons for ARSE. 
Five unrelated patients (PAR492, PAR484, BA439, 
BA440, and NAN514) were found to have a band mobility 
shift in ARSE exons not present in any of the controls, in 
all five cases, missense mutations were identified by direct 
sequence analysis using ol igonucleotides from the flank- 
ing introns. Types and positions of the mutations are listed 
in Table 1. The absence of these mutations in 120 normal 
X chromosomes suggests that they are responsible for 
CDPX. Figure 4 shows the sequence analysis of exon 4 
of the ARSE gene in patient PAR492 in whom the G137V 
mutation was identified. This mutation is of particular inter- 
est, since the Gly at position 137 is conserved in all sul- 
fatases and a mutation in the ARSB gene causing an iden- 
tical amino acid substitution has been described in a 
patient with mucopolysaccharidosis VI (Maroteaux-Lamy 
syndrome) (Wicker et al., 1991). 
Biochemical Characterization of ARSE Gene 
Product in COS Cells 
Transient expression of ARSE in COS cells was obtained 
by subcloning the cDNA in the pcDL-SRe296 vector (Ta- 
kebe et al., 1988). As negative controls, COS cells were 
also transfected in parallel with vector alone and with a 
construct carrying the ARSE cDNA in the antisense orien- 
tation. Expression of the ARSC/STS cDNA, subcloned in 
the same vector, was performed in parallel for comparison. 
The results of enzymatic determinations performed at neu- 
tral pH using COS cell extracts 48-76 hr after transfection 
are shown in Table 2. They indicate that the ARSE gene 
product is an arylsulfatase, as demonstrated by the 6- to 
8-fold increase of enzymatic activity observed when 4-MU 
sulfate was used as a substrate. Unlike ARSC/STS, ARSE 
has no activity toward steroid sulfates such as dehydroepi- 
Table 1. ARSE Gene Mutations in Patients with CDPX 
Nucleotide Amino Acid 
Patient Substitution Change Exon 
BA440 G ~ C Arg-12 ~ Ser 2 
NAN514 G ~ A Gly-117 ~ Arg 4 
BA439 G ~ C Arg-111 ~ Pro 4 
PAR492 G ~ T Gly-137 ~ Val 4 
PAR484 G ~ C Gly-245 ~ Arg 5 
Primers Used ~r Annealing 
SSCP Anal~is Temperature 
F 5 ' - ca tacacaagt tc tgcaaat8 -3 '  51oC 
R 5Lcagtggct tc tc t t tc t tc .3 ,  
F5~ccaagtgt tc ta t t t t tg -3 '  48oC 
R 5~ccaaactc t t tagctgaatg -3  , 
F5~ccaastgt tc ta t t t t t s -3 '  48oc 
R 5~ccaaactc t t tasc tsaats .3 ,  
F5~ccaagtgt tc ta t t t t tg -3 '  48oC 
R 5Lccaaactc t t tasc tgaats -3  , 
F 5Lcsacatgtccast ta tsc tcag-3  , 58oc 
R 5~cat tccaaasctsagt@ctts -3 '  
Cell 
20 
WT P 
GLY 137 
WT AAA[~ATGCCACTGGAC 
P AAA~ATGCCACTGGAC 
VAL 
Figure 4. Sequence Analysis of the G137V Mutation 
Genomic DNA from patient PAR492 (P) and from a normal individual 
(WT) was amplified using primers flanking exon 4 (see Table 1) and 
sequenced. Sequencing reactions were loaded in the following order: 
A, C, G, T. The arrows indicate the position of the G to T transversion. 
A comparison between patient and wild-type sequences in the region 
where the G137V mutation is located is shown at the bottom. 
androsterone sulfate (DHEAS) and estrone sulfate (ES). 
ARSE activity can be distinguished from ARSC since it is 
not competitively inhibited by DHEAS (Figure 5A) and is 
more heat labile (Figure 5B). 
ARSE Is Inhibited by Warfarin 
Because of the phenotypic similarities of CDPX and warfa- 
rin embryopathy, we speculated that warfarin might inter- 
fere with ARSE activity. Figu re 5C shows ARSE and ARSC 
activities in transfected COS cells in the presence of in- 
creasing warfarin concentrations. A significant decrease 
of ARSE activity was observed starting at concentrations 
between 10 and 50 p.M and reaching a complete inhibition 
at 5 mM. ARSC activity remained constant even at the 
highest warfarin concentrations. These data indicate that 
ARSE is inhibited by warfarin. 
Arylsulfatase Activity in CDPX 
Based on the above described data, one would expect 
that patients with CDPX lack an arylsulfatase activity that 
is biochemically distinct from the other arylsulfatases. To 
test this hypothesis, we have developed a specific assay 
to measure ARSE activity in fibroblasts from these pa- 
tients. A major problem in developing such a test is the 
interference of ARSC activity at neutral pH. Therefore, the 
enzymatic assay was run in the presence of DHEAS, a 
natural substrate of ARSC/STS protein, which competi- 
tively inhibits ARSC. Under these conditions, approxi- 
mately 70%-90% of the measurable arylsulfatase activity 
is heat labile. Figure 6 shows the results of enzymatic 
assays performed in control and patient fibroblasts. The 
heat-labile arylsulfatase activity ranged from 350-850 
pmol/mg/hr in six control cell lines and in fibroblasts from 
four patients with isolated X-linked ichthyosis (BA65, 
BA67, BA88, and BA16) who have a deletion of the ARSC/ 
STS gene. This heat-labile nzymatic activity represents 
a tiny portion of the total neutral arylsulfatase activity and, 
therefore, can be easily overlooked under the assay condi- 
tions commonly used for ARSC measurement. We have 
Table 2. Expression of ARSC and ARSE in COS Cells 
Estrone 
Construct 4-MU Sulfate a DHEA Sulfate b Sulfate b 
pcDL-SR~296 3.3 65 293 
pcDL-SR~296-18- 3.0 268 378 
(ARSE antisense) 
pcDL-SRa296-TA5B 66.0-93.5 9,758 31,847 
(ARSC/STS) 
pcDL-SRa296-12 + 19.5-25.7 172 387 
(ARSE sense) 
, Activities expressed as nmoles/mg/hr, bActivities expressed as 
pmoles/mg/hr. 
tested fibroblasts from a patient (BA311) with a deletion 
of the CDPX critical region and from three patients (BA20, 
BA424, and BA423) with large Xp22.3 deletions panning 
both the CDPX critical region and the ARSC/STS gene 
(Schaefer et al., 1993). In all of these patients, as well as 
in two patients with MSD (BA426 and BA428), we have 
found a profound deficiency of a heat-labile DHEAS- 
resistant arylsulfatase activity. Cell line BA311 has a com- 
plete deficiency of a heat-labile arylsulfatase activity, while 
both ARSC and STS activities are normal. Conversely, in 
patients affected by isolated X-linked ichthyosis, heat- 
labile arylsulfatase activity is normal (Figure 6). 
The combination of these results points to the existence 
of a neutral arylsulfatase activity that is deficient in patients 
with deletions of the CDPX critical region and is distinct 
from ARSC. Genetic and biochemical data indicate that 
this neutral arylsulfatase is the product of the ARSE gene. 
However, we cannot exclude the possibility that ARSD 
and ARSF gene products may contribute to this activity. 
Biochemical characterization f ARSD and ARSF gene 
products and the study of patients with point mutations in 
the ARSE gene might help to clarify this issue. Unfortu- 
nately, flbroblasts from these patients are not available at 
this time. 
Discussion 
A Cluster of Sulfatase Genes on Xp22.3 
We have identified three novel genes on the X chromo- 
some sharing homology with all members of the sulfatase 
gene family: ARSD, ARSE, and ARSF. Unlike all other 
members of this family, these genes were isolated by posi- 
tional cloning, a strategy that does not rely on the knowl- 
edge of the gene product. This approach often leads to 
the discovery of novel metabolic pathways that had not 
been predicted by classical biochemical studies. 
ARSD, ARSE, and ARSF are positioned in tandem in 
a small region on Xp22.3. Sequence and structural similar- 
ities among these genes uggest that they were generated 
by ancient duplications. Duplications are not unprece- 
dented in this region of the human genome. For example, 
evidence has been presented that tandem duplications in 
the pseudoautosomal region resulted in the presence of 
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Figure 5. Biochemical Studies of ARSE Expressed in COS Cells 
Homogenates from COS cells transfected with either ARSE or with 
ARSC/STS cDNAs were used in three different sets of experiments. 
(A) Competitive inhibition by DHEAS. Neutral arylsulfatase assays 
were run as described in the Experimental Procedures either with, or 
without, adding DHEAS to the incubation mix. No competition was 
observed on ARSE activity (86.0% activity with DHEAS), while ARSC 
was almost completely inhibited (4.60/o activity). 
(B) Time course of heat inactivation of ARSE. COS cell extracts were 
incubated at 50°C for the times indicated and used for neutral arylsulfa- 
tase activity determinations. ARSE activity was almost completely in- 
activated within 10 rain of incubation at 50°C, while ARSC activity 
remained constant after incubation times up to 60 rain. 
(C) Warfarin inhibition of ARSE. Neutral arylsulfatase assay was run 
in the presence of increasing concentrations of warfarin. The average 
values of three separate measurements and the standard deviations 
are shown. ARSE activity inhibition was observed starting at concen- 
trations of 10 I~M and was almost complete at 5 mM (15% activity). 
ARSC was not affected by the presence of warfarin in the incubation 
mixture. 
homologous loci MIC2, MIC2R, and PBDX (Smith and 
Goodfellow, 1994). An obl igatory crossing-over event oc- 
curs in this region of the X and Y chromosomes at each 
male meiosis, and this extremely high frequency of recom- 
bination may render this region more prone to unequal 
crossing-over, leading to deletions and duplications. The 
ARSD, ARSE, and ARSF loci are located only 150 kb from 
the pseudoautosomal boundary. We propose that this 
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Figure 6. Enzymatic Analysis in Fibroblasts from Patients 
Enzymatic determinations were performed in six normal individuals, 
four patients with XLI carrying a deletion of the ARSC/STS gene, one 
patient with a deletion of the CDPX critical region, two patients with 
MSD, and three patients with Xp22.3 deletions spanning both the 
ARSC/STS gene and the CDPX critical region. ARSC activity is ex- 
pressed as mmol 4-MU liberated/mg protein/hr, STS as pmol DHEA 
liberated/rag protein/hr, and heat-labile arylsulfatase as pmol 4-MU 
liberated/mg protein/hr. The average values of three separate mea- 
surements and the standard deviations are shown. A profound defi- 
ciency of a heat-labile neutral arylsulfatase activity was observed in 
patients with deletions panning the CDPX critical region. In patients 
with XLI, this activity is normal. The CDPX patient has normal ARSC 
and STS activities, while both activities are deficient in MSD and XLI/ 
CDPX patients. 
cluster of three genes was generated by unequal crossing- 
over events that occurred in an ancestral pseudoautoso- 
mal region. The repositioning of the pseudoautosomal 
boundary more telomeric on Xp may have allowed the X 
and Y copies of these genes to diverge, with subsequent 
loss of function of the Y copies. A similar mechanism was 
proposed for the STS and KAL genes (Yen et al., 1988; 
del Castillo et al., 1992; Incerti et al., 1992). The finding 
that at least two of these novel genes (ARSD and ARSE) 
escape X inactivation, as well as the detection of homolo- 
gous loci on the Y chromosome, supports this hypothesis. 
The identification of three genes from the CDPX critical 
region encoding putative sulfatases suggested the possi- 
bility that CDPX was due to a sulfatase deficiency. The 
observation of at least two patients with MSD who had 
typical radiological and facial features of CDPX, one pres- 
enting at birth (Burch et al., 1986) and the other who died 
in utero (J. Hopwood, personal communication), strongly 
supports this hypothesis. As features of CDPX are rela- 
t ively mild, compared with the other features of MSD, and 
tend to fade with age, they may have been overlooked in 
other cases with MSD. 
The ARSE Gene Is Mutated in CDPX 
As ARSD, ARSE, and ARSF genes are all located within 
the CDPX critical region, it was difficult to establish which 
one of these three genes was specifically involved in the 
pathogenesis of CDPX. The presence of substantial se- 
quence divergence among these three genes, as shown 
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by lack of cross-hybridization, suggests that they may 
have a different function as the result of a different sub- 
strate specificity. This is also supported by the presence 
of different expression patterns, ARSD being quite ubiqui- 
tously expressed and ARSE being expressed exclusively 
in liver, pancreas, and kidney. 
We searched for point mutations in both ARSD and 
ARSE genes in a heterogeneous group of 27 unrelated 
male patients displaying features of CDPX. Five missense 
mutations in the ARSE gene were identified. One can sug- 
gest that these mutations are related to the occurrence 
of CDPX on the basis of the following observations. None 
of the mutations were found in any of 60 normal female 
individuals, corresponding to 120 normal X chromosomes. 
Some of the mutations resulted in nonconservative amino 
acid substitutions, such as the R111P mutation changing 
a basic amino acid to a (turn inducer) neutral hydrophobic 
one, or the G137V changing a polar amino acid to a hy- 
drophobic one. This latter mutation, located in a highly 
conserved domain, substitutes a glycine residue that is 
found at the same position in all previously described sul- 
fatases in human and other species, including E. coli (Dan- 
iels et al., 1992) and K. aerogenes (Murooka et al., 1990). 
Furthermore, a mutation in a different sulfatase gene, 
ARSB, resulting in a glycine to valine substitution at ex- 
actly the same position was described by Wicker et al. 
(1991) in a patient with mucopolysaccharidosis VI (Maro- 
teaux-Lamy syndrome). This mutation severely impaired 
the processing and stability of ARSB precursor polypep- 
tides that are not converted to mature ARSB and undergo 
rapid proteolytic degradation, as shown by the analysis 
of fibroblasts from the patient and by the expression of 
this mutation in LTK- cells. These authors speculated that 
the glycine at position 137 is of crucial importance for the 
secondary structure of the arylsulfatases, since it appears 
to be located at a junction between an ~ helix and a 13 
sheet (Wicker et al., 1991). 
These data implicate ARSE in the pathogenesis of 
CDPX. The fact that we could detect ARSE mutations in 
only a fraction of all patients with the CDPX phenotype 
referred to us for molecular analysis would be consistent 
with the presence of genetic heterogeneity for CDPX. 
Since only 9 out of 11 exons of the ARSE gene have been 
screened for mutations, additional mutations may be 
found in the remaining two exons (exons 1 and 2). Further- 
more, we cannot exclude the possibility that mutations in 
the ARSD or ARSF genes may also cause CDPX. 
CDPX Due to ARSE Deficiency 
Previous studies reported data suggesting the presence 
of two variants of ARSC based on both electrophoresis 
and immunoprecipitation studies. These two variants were 
designated F (faster migrating) and S (slowly migrating). 
Only the latter of these two variants appeared to corre- 
spond to STS, the other being a separate entity (Chang 
et al., 1990). We have identified a gene encoding an aryl- 
sulfatase with the same biochemical features and tissue 
distribution of the previously reported "F form" of ARSC. 
Expression of ARSE cDNA in COS cells demonstrated 
that ARSE is heat labile, has a neutral pH optimum (data 
not shown), is inactive against steroid sulfates, and is not 
competitively inhibited by them. Enzyme analysis of fibro- 
blasts from patients with CDPX carrying deletions span- 
ning the ARSE gene and from patients with MSD demon- 
strated a deficiency of a heat-labile arylsulfatase activity 
that, most likely, corresponds to the product of the ARSE 
gene. Together, these data indicate that CDPX is an inborn 
error of metabolism due to deficiency of ARSE. 
Physiological Role of ARSE and the 
Warfarin Embryopathy 
Warfarin, a coumarin derivative that inhibits vitamin K re- 
ductase activity (Fasco et al., 1982), interferes with normal 
cartilage and bone development. Warfarin embryopathy, 
a well-known human teratologic syndrome that is the con. 
sequence of maternal use of warfarin between 6 and 9 
postconceptual weeks (Hall et al., 1980), results in skeletal 
and facial abnormalities strikingly similar to those of CDPX 
(Pauli, 1988). Rats treated with warfarin develop skeletal 
changes characterized by excessive mineralization and 
growth plate closure of long bones, associated with snout 
dysmorphisms (Price, 1985; Howe and Webster, 1992). 
A phenocopy of CDPX and of warfarin embryopathy is the 
congenital deficiency of vitamin K epoxide reductase, the 
enzyme recycling vitamin K epoxide to vitamin K (Pauli et 
al., 1987). These observations indicate the importance of 
vitamin K in bone and cartilage development. This is fur- 
ther emphasized by the involvement of vitamin K in the 
carboxylation of bone Gla protein and of matrix Gla pro. 
tein, two essential components of bone and cartilage 
(Price, 1985). The striking similarities among CDPX, war- 
farin embryopathy, and vitamin K epoxide reductase defi- 
ciency phenotypes and the evidence that warfarin inhibits 
ARSE both suggest that these disorders are due to abnor- 
malities in the same metabolic pathway. However, since 
warfarin concentrations required for inhibition of ARSE 
activity are high, we cannot rule out the possibility that 
ARSE is not the direct target of the drug in warfarin em- 
bryopathy. 
The physiological role of ARSE and the mechanisms by 
which its deficiency leads to the skeletal changes typical 
of CDPX are not understood. A major unresolved issue 
is the identity of the natural substrate for ARSE. The nature 
of the CDPX phenotype suggests that ARSE may be es- 
sential for the correct composition of cartilage and bone 
matrix during bone development. The importance of sev- 
eral lysosomal sulfatases in cartilage and bone develop- 
ment is evident from their involvement in the catabolic 
pathway of sulfated glycosaminoglycans, which are es- 
sential components of the extracellular matrix of cartilage. 
Accordingly, bone and cartilage abnormalities are present 
in other sulfatase deficiencies, such as in mucopolysac- 
charidoses type II, IIID, IVA, and VI (Neufeld and Muenzer, 
1995). However, differences in pH optima between ARSE 
and lysosomal sulfatases indicate that they have different 
subcellular localization and, therefore, different metabolic 
functions. The recent finding of a sulfate transport defect 
in diastrophic dysplasia, an osteochondrodysplasia that 
is characterized by dwarfism, spinal deformation, and joint 
abnormalities, further emphasizes the importance of sul- 
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fate metabol ism in cart i lage and bone  deve lopment  (H&st- 
backa  et al., 1994). 
In conc lus ion,  our  data suggest  that a su l fatase defi-  
c iency is respons ib le  for bone  and cart i lage changes  in 
both genet ic  and drug- induced human disorders.  Further  
studies are needed to character i ze  the relat ive roles of 
ARSE and v i tamin K in bone  and cart i lage deve lopment  
and to unders tand  ful ly the metabol ic  pathway that is im- 
pa i red in CDPX and in warfar in  ernbryopathy.  
Experimental Procedures 
Patients and Cell Lines 
The 27 patients (23 sporadic and 4 familial) tested for point mutations 
in the ARSD and ARSE genes had the typical radiological and clinical 
features of CDPX. Some of these patients have been described in 
previous reports (Sheffield et al., 1976; Maroteaux, 1989). Patient 
PAR492, in whom the G137V mutation was identified, corresponds 
to case 1 in a previous report (Maroteaux, 1989). Fibroblast cell lines 
BA65, BA67, BA88, and BA16 are from patients with X-linked ichthyo- 
sis (XLI) carrying a deletion of the STS gene. BA311 is from a patient 
with CDPX carrying an X/Y translocation involving the Xp22.3 region 
(Wang et al., 1995). BA428 cell line (Burch et al., 1986), a gift from Dr. 
Fensom, and BA426, obtained from the Human Mutant Cell Repository 
(cell line GM3245), are from patients with MSD. BA20, BA423, and 
BA424 (Schaefer et al., 1993) are from patients with terminal Xp dele- 
tions involving both the CDPX and STS loci. 
Physical Mapping 
We have employed a previously described strategy to identify overlap- 
ping cosmid clones using entire YACs as probes (Wapenaar et al., 
1994). YAC clones spanning the CDPX region (Figure 1) are described 
in Wang et aL (1995). Yeast DNA preparation, screening of the X-chro- 
mosome specific cosmid library using purified DNA from YACs 
NB6F12 and 455B10, and construction of cosmid contigs were per- 
formed as previously described (Wapenaar et al., 1994). Two cosmid 
contigs, spanning 340 kb of the CDPX critical region (with a gap of 
60 kb), were assembled. 
Exon Amplification 
Four cosmid clones belonging to the first contig (clones 16, 76, 75, 
and 48) and five belonging to the second ~clones 32, 66, 58, 96, and 
100) were used for exon amplification experiments. The cosmid clones 
were individually digested with BamHI-Bglll, cloned in the pSPL3 vec- 
tor, and used for the exon amplification experiments as previously 
described (Church et al., 1994). 
Screening of eDNA Libraries 
An adult human kidney cDNA library, oligo(dT) + random primed (Clon- 
tech HL1123n), was plated at a density of 1 x 106 PFU and screened 
using exon amplification products as probes. Hybridization and wash- 
ing conditions were as previously described (Franco et al., 1991). To 
validate the 5' end of ARSD transcript, 5'-RACE-PCR was performed 
as previously described (Frohman et al., 1988). 
DNA Sequence Analysis 
Consensus cDNA sequences spanning the entire coding regions of 
the ARSD and ARSE genes were obtained by end sequencing of over- 
lapping cDNA clones and by primer walking. Sequencing was per- 
formed either man ually, using a Seq uenase Version 2.0 DNA Sequenc- 
ing kit (United States Biochemical), or automatically, using an Applied 
Biosystem ABI 373A fluorescence sequencer. Assembly and analysis 
of DNA sequences were performed using the facilities of the Molecular 
Biology Information Resource, Department of Cell Biology, Baylor Col- 
lege of Medicine. Data base searches were carried out using the GCG 
software package and the BLAST network service from the National 
Center for Biotechnology Information. The multiple sequence align- 
ment shown in Figure 2 was performed using the pattern-induced 
multisequenoe alignment (PIMA) algorithm (Smith and Smith, 1992). 
mRNA Analysis 
Northern blots containing human RNAs from several tissues were pur- 
chased from Clontech and hybridized to exons 76.15 and 48.7 from 
the ARSD and ARSE genes, respectively, using the conditions recom- 
mended by the manufacturer (Clontech). Washing conditions were 
0.1 x SSC, 0.2% SDS at 50°C for both probes. Fibroblasts from a 
normal male individual and a somatic cell hybrid (BA342) retaining 
the inactive X chromosome were used for the X inactivation studies. 
RT-PCR experiments were performed as previously described (Bor- 
sani et al., 1991). The following oligonucleotide primers were used: 
ARSD F, GAGGAAGGTGTGAGGCTC; ARSD R, CCTGAGCCTGCG- 
I-rCCACTG; ARSE F, GTCTCAACTGTGAGTCAG; ARSE R, AAGTT- 
CTCCATAGTGATAA. 
PCR was carried out for 40 cycles. Annealing temperatures were 
50°C for ARSD and ARSE primers. MIC2 and PGK1 PCR conditions 
and primers were as previously described (Brown et al., 1990; Franco 
et al., 1991). 
SSCP Analysis 
SSCP analysis was performed on amplified genomic DNA from pa- 
tients according to a previously described method (Orita et al., 1989). 
Direct sequencing was carried out on PCR products purified from a 
2% low melting agarose gel (Nusieve FMC), using a Sequenase 2.0 
kit (United States Biochemical). 
Expression of ARSC and ARSE in Eukaryotic Cells 
ARSC/STS cDNA (Ballabio et al., 1987) was subcloned in EcoRI- 
digested plasmid pcDL-SRa296 (Takebe et al., 1988). ARSE cDNA, 
obtained by ligating two different cDNA clones, was blunt ended and 
subcloned in the same vector. COS cells were transfected with 10- 
20 I~g of either construct by electi'oporation and harvested by trypsin- 
ization 48-76 hr after transfection for enzyme assays. 
Enzyme Assays 
Fibroblast extracts were prepared as previously described (Chang et 
al, 1985). COS cells were resuspended in 0.1 M Tris-HCI (pH 7.5), 
1% Triton X-100, and 150 mM NaCI. Neutral arylsulfatase activity 
assay conditions were as follows: the incubation mixture (200 p.I) con- 
tained 30-40 I~g of protein, 0.2 mmol/I 4-MU sulfate, in 0.05 M Tris- 
HCI buffer (pH 7.5). The enzymatic assay was run at 37°C for 4 hr. 
The reaction was stopped by adding 1.8 ml of glycine-carbonate buffer 
(pH 10.7), and fluorescence was determined at 365 nm (excitation) 
and 460 nm (emission) on a Hoefer TKO 100 fluorometer. Warfarin 
inhibition analysis was performed by adding 3-(~z-acetonylbenzyl)-4- 
hydroxycoumarin (warfarin) sodium salt (Sigma A-3430) at different 
concentrations to the incubation mix. 
To measure heat-labile, non-STS, arylsulfatase activity, part of the 
fibroblast extract was inactivated for 15 rain at 50°C, while the noninac- 
tivated samples were kept in ice. The assay was performed in the 
presence of 0.6 mmol/I DHEA sulfate (DHEAS) in the incubation mix- 
ture. The enzymatic activity was calculated as the difference between 
the activities of heat-inactivated and noninactivated samples. DHEA 
and estrone sulfatase activities were measured as previously de- 
scribed (Ballabio et al., 1985; Munroe and Chang, 1987). 
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